https://finance.yahoo.com/news/daily-biotech-pulse-kazia-jumps-122945401.html
"Stocks In Focus Kazia To Present Positive Mid-stage Results For Brain Tumor Drug
Announcing summary of its scheduled presentation at the Society for Neuro-Oncology annual meeting, Kazia Therapeutics Ltd (NASDAQ: KZIA) said new interim analysis of paxalisib phase 2 study in glioblastoma is highly consistent with prior data.Median progression-free survival was 8.4 months compared to 5.3 months for the existing standard-of-care temozolomide, and median overall survival was also better at 17.5 months versus 12.7 months. Safety at 60mg dose showed profile similar to prior experience, with the most common toxicities including rash, mouth ulcers, and hyperglycemia, consistent with other PI3K and mTOR inhibitors.
The stock was jumping 19.13% to $11.77 in premarket trading Wednesday."
https://finance.yahoo.com/news/daily-biotech-pulse-kazia-jumps-12...
-
- There are more pages in this discussion • 569 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)